Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 413

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Anti–microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways

Open access
Gomez, Ivan G., MacKenna, Deidre A., Johnson, Bryce G., Kaimal, Vivek, Roach, Allie M., Ren, Shuyu, Nakagawa, Naoki, Xin, Cuiyan, Newitt, Rick, Pandya, Shweta, Xia, Tai-He, Liu, Xueqing, Borza, Dorin-Bogdan, Grafals, Monica, Shankland, Stuart J., Himmelfarb, Jonathan, Portilla, Didier, Liu, Shiguang, Chau, B. Nelson, Duffield, Jeremy S.·2015·Journal of Clinical Investigation

Abstract

MicroRNA-21 (miR-21) contributes to the pathogenesis of fibrogenic diseases in multiple organs, including the kidneys, potentially by silencing metabolic pathways that are critical for cellular ATP generation, ROS production, and inflammatory signaling. Here, we developed highly specific oligonucleotides that distribute to the kidney and inhibit miR-21 function when administered subcutaneously and evaluated the therapeutic potential of these anti-miR-21 oligonucleotides in chronic kidney disease. In a murine model of Alport nephropathy, miR-21 silencing did not produce any adverse effects and resulted in substantially milder kidney disease, with minimal albuminuria and dysfunction, compared with vehicle-treated mice. miR-21 silencing dramatically improved survival of Alport mice and reduced histological end points, including glomerulosclerosis, interstitial fibrosis, tubular injury, and inflammation. Anti-miR-21 enhanced PPARα/retinoid X receptor (PPARα/RXR) activity and downstream signaling pathways in glomerular, tubular, and interstitial cells. Moreover, miR-21 silencing enhanced mitochondrial function, which reduced mitochondrial ROS production and thus preserved tubular functions. Inhibition of miR-21 was protective against TGF-β-induced fibrogenesis and inflammation in glomerular and interstitial cells, likely as the result of enhanced PPARα/RXR activity and improved mitochondrial function. Together, these results demonstrate that inhibition of miR-21 represents a potential therapeutic strategy for chronic kidney diseases including Alport nephropathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci75852

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 413

Metadata

Authors
Gomez, I. G., MacKenna, D. A., Johnson, B. G., Kaimal, V., Roach, A. M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., Xia, T.-H., Liu, X., Borza, D.-B., Grafals, M., Shankland, S. J., Himmelfarb, J., Portilla, D., Liu, S., Chau, B. N., & Duffield, J. S.
Venue
Journal of Clinical Investigation
Published
2014-11-21
Volume
125
Issue
1
Pages
141-156
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2102750482
Cited by
413
References
48
FWCI
21.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti–microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. https://app.cochat.ai/papers/10.1172/jci75852
The paper
Gomez, I. G., MacKenna, D. A., Johnson, B. G., Kaimal, V., Roach, A. M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., Xia, T.-H., Liu, X., Borza, D.-B., Grafals, M., Shankland, S. J., Himmelfarb, J., Portilla, D., Liu, S., Chau, B. N., & Duffield, J. S. (2015). Anti–microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. Journal of Clinical Investigation. https://doi.org/10.1172/jci75852

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.